Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,019 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 19,019 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F5: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby daughter | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectby son | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | Indirectby daughter | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
F5: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Twist Bioscience Corp
Report date August 07, 2026 · Filed August 11, 2026
Section 16 reporting ended · disclosed 2026-02-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,084 |
Ending reported balance
After 2026-08-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-07 · Exercise / conversion · Acquired 18,417 · Balance 39,501 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. Row 2 · 2026-08-07 · Sale · Disposed 18,417 · Balance 21,084 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2028-09-13 | Direct | 0 |
Reported balance
After 2026-08-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-07 · Exercise / conversion · Disposed 18,417 · Balance 0 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. F3: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy the Chess 1997 Trust | 42,528 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 42,528 F2: The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026.
F2: The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.
F3: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 26, 2026 00:22 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 4,000 | $0.00 Strike: $57.66 | $0.00 |
DisclosureSEC source: 0001193125-26-403101 · ownership.xml · derivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2034-09-22 F5 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. Read SEC document |
| September 23, 2026 Filed Sep 26, 2026 00:22 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-403101 · ownership.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,019 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 23, 2026. F3 · balance_after: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 18,417 | $0.00 Strike: $11.89 | $0.00 |
DisclosureSEC source: 0001214659-26-009894 · marketforms-73745.xml · derivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,417 shares Expires 2028-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. F3 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 18,417 | $110.89 | $2,042,261.13 |
DisclosureSEC source: 0001214659-26-009894 · marketforms-73745.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,084 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 18,417 | $11.89 | $218,978.13 |
DisclosureSEC source: 0001214659-26-009894 · marketforms-73745.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $11.89 | $0.00 |
DisclosureSEC source: 0001214659-26-003483 · marketforms-72606.xml · derivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,417 Underlying: Common Stock · 10,000 shares Expires 2028-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 10, 2025. F3 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 10,000 | $47.00 | $470,000.00 |
DisclosureSEC source: 0001214659-26-003483 · marketforms-72606.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,084 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 10, 2025. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 10,000 | $11.89 | $118,900.00 |
DisclosureSEC source: 0001214659-26-003483 · marketforms-72606.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 10, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,184 | $48.26 | $105,402.02 |
DisclosureSEC source: 0001214659-26-002125 · marketforms-72222.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,084 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior election by the Reporting Person and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 5,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-001342 · marketforms-72064.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,268 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 23:51 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 8,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001193125-25-227235 · ownership.xml · derivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,940 | $53.14 | $156,216.90 |
DisclosureSEC source: 0001214659-25-002410 · marketforms-68048.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,173 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior irrevocable election by the Reporting Person and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 4,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-002229 · marketforms-68033.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,113 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,000 | $50.00 | $250,000.00 |
DisclosureSEC source: 0001214659-25-000445 · marketforms-67813.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,641 F1 · shares: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. Read SEC document |
| December 05, 2024 Filed Dec 30, 2024 21:55 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 3,504 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-24-021151 · marketforms-67664.xml · derivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,504 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. F5 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 05, 2024 Filed Dec 30, 2024 21:55 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 709 | $52.45 | $37,187.83 |
DisclosureSEC source: 0001214659-24-021151 · marketforms-67664.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,641 F1 · shares: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $52.37 to $52.74 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 05, 2024 Filed Dec 30, 2024 21:55 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,795 | $51.70 | $144,508.49 |
DisclosureSEC source: 0001214659-24-021151 · marketforms-67664.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,350 F1 · shares: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $51.25 to $52.04 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 05, 2024 Filed Dec 30, 2024 21:55 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 3,504 | $8.82 | $30,905.28 |
DisclosureSEC source: 0001214659-24-021151 · marketforms-67664.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 3,600 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0000950170-24-126641 · ownership.xml · derivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,504 Underlying: Common Stock · 3,600 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. F5 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,276 | $47.76 | $60,935.38 |
DisclosureSEC source: 0000950170-24-126641 · ownership.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,641 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $47.50 to $47.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,324 | $46.99 | $109,203.37 |
DisclosureSEC source: 0000950170-24-126641 · ownership.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,917 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $46.50 to $47.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 3,600 | $8.82 | $31,752.00 |
DisclosureSEC source: 0000950170-24-126641 · ownership.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 12, 2024. Read SEC document |
| September 18, 2024 Filed Jan 18, 2025 01:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 120,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-006887 · ownership.xml · derivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-09-17 F1 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 18, 2024. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 19,500 | $1.20 | $23,400.00 |
DisclosureSEC source: 0000950170-24-073851 · ownership.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,273 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.19 to $1.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,110 | $34.98 | $143,784.24 |
DisclosureSEC source: 0001214659-24-002250 · marketforms-64631.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,169 F2 · shares: Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 21:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 5,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-002250 · marketforms-64631.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,279 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 00:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 85,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-23-050222 · doc4.xml · derivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-09-18 F5 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:15 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 8,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001879 · marketforms-59382.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,464 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 23:23 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,100 | $3.19 | $16,269.00 |
DisclosureSEC source: 0001209191-22-051303 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,179 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.13 to $3.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 22, 2022 Filed Sep 21, 2023 00:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,200 | $0.67 | $6,834.00 |
DisclosureSEC source: 0001209191-23-050222 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,773 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.66 to $0.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: Includes 56,794 shares previously reported as shares held in Grantor Retained Annuity Trusts for which the reporting person was the sole trustee. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,400 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-22-050812 · doc4.xml · derivative · entry 7 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2030-09-15 F4 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050812 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,279 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 16, 2022. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 3,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-002208 · marketforms-55356.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,252 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 253 | $58.88 | $14,896.39 |
DisclosureSEC source: 0001214659-22-002067 · marketforms-55332.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,761 F1 · kind: Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,000 | $120.15 | $480,613.60 |
DisclosureSEC source: 0001214659-21-011105 · marketforms-54137.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,014 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.00 to $120.89 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 21:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,700 | $120.15 | $444,540.20 |
DisclosureSEC source: 0001214659-21-010741 · marketforms-54063.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,014 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.00 to $120.47 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 300 | $120.00 | $36,000.00 |
DisclosureSEC source: 0001214659-21-010680 · marketforms-54033.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,714 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,400 | $0.00 Strike: $17.78 | $0.00 |
DisclosureSEC source: 0001209191-21-057703 · doc4.xml · derivative · entry 6 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2029-09-21 F6 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,600 | $17.94 | $82,524.00 |
DisclosureSEC source: 0001209191-21-057703 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,873 F3 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $17.59 to $18.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issues. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057703 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,473 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 22, 2021. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,000 | $120.23 | $480,908.40 |
DisclosureSEC source: 0001214659-21-009507 · marketforms-53808.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,014 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.00 to $120.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 10,279 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-21-055543 · doc4.xml · derivative · entry 9 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,279 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on September 18, 2021. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,279 | $16.02 | $164,669.58 |
DisclosureSEC source: 0001209191-21-055543 · doc4.xml · nonDerivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,273 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on September 18, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $15.76 to $16.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 10,279 | $13.80 | $141,850.20 |
DisclosureSEC source: 0001209191-21-055543 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on September 18, 2021. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 8,000 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-21-055543 · doc4.xml · derivative · entry 8 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,279 Underlying: Common Stock · 8,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on September 18, 2021. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,000 | $16.00 | $128,000.00 |
DisclosureSEC source: 0001209191-21-055543 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,273 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on September 18, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.85 to $16.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $13.80 | $110,400.00 |
DisclosureSEC source: 0001209191-21-055543 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on September 18, 2021. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GiftCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053541 · doc4.xml · nonDerivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by son Disclosed balance after: 2,100 F1 · kind: This transaction involved a gift of shares by the reporting person to his children. F2 · balance_after: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GiftCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053541 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 2,100 F1 · kind: This transaction involved a gift of shares by the reporting person to his children. F2 · balance_after: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GiftCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053541 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 2,100 F1 · kind: This transaction involved a gift of shares by the reporting person to his children. F2 · balance_after: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.